Mosaic ImmunoEngineering Inc. financial data

Symbol
CPMV on OTC
Location
9114 Adams Ave., #202, Huntington Beach, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
PATRIOT SCIENTIFIC CORP (to 11/19/2020)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.31 % -76.3%
Debt-to-equity -101 % +3.27%
Return On Equity 14.2 % -22.8%
Return On Assets -1.35K % -229%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.24M shares 0%
Common Stock, Shares, Outstanding 7.24M shares 0%
Entity Public Float 466K USD -43%
Common Stock, Value, Issued 72 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.24M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7.24M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 184K USD -57.8%
General and Administrative Expense 696K USD -27.8%
Operating Income (Loss) -880K USD +37.2%
Nonoperating Income (Expense) -39.9K USD -110%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -920K USD +8.58%
Income Tax Expense (Benefit) 2.4K USD 0%
Net Income (Loss) Attributable to Parent -922K USD +8.56%
Earnings Per Share, Basic -0.13 USD/shares +7.14%
Earnings Per Share, Diluted -0.13 USD/shares +7.14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115K USD -26.4%
Assets, Current 142K USD -21.1%
Assets 142K USD -21.1%
Accounts Payable, Current 135K USD +13.8%
Employee-related Liabilities, Current 3.77M USD +18.3%
Accrued Liabilities, Current 647K USD +0.79%
Liabilities, Current 5.54M USD +17%
Liabilities 6.93M USD +14.5%
Retained Earnings (Accumulated Deficit) -8.84M USD -11.6%
Stockholders' Equity Attributable to Parent -6.79M USD -15.6%
Liabilities and Equity 142K USD -21.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -91.1K USD +47%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 7.24M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115K USD -26.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 3.5M USD +11.2%
Deferred Tax Assets, Operating Loss Carryforwards 686K USD +55.1%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 2.05M USD +0.24%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.87K USD -10%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%